Notícias18/11/2021 SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic caused by it, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)... Repositório Covid-1918/11/2021 Organ-specific genome diversity of replication-competent SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not always confined to the respiratory system, as it impacts people... Repositório Covid-1918/11/2021 Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2SARS-CoV-2 is the third coronavirus to have caused severe disease in humans in the last two decades, with approximately 5%... Repositório Covid-1916/11/2021 Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2COVID-19, for which no confirmed therapeutic agents are available, has claimed over 48,14,000 lives globally. A feasible and quicker method... Repositório Covid-1916/11/2021 Two years into COVID-19 – Lessons in SARS-CoV-2 and a perspective from papers in FEBS LettersThe 2019 outbreak of coronavirus disease (COVID-19) in Wuhan (Hubei province of China) has given rise to a pandemic spread... Repositório Covid-1915/11/2021 COMPARISON OF REMDESIVIR AND FAVIPIRAVIR - THE ANTI-COVID-19 AGENTS MIMICKING PURINE RNA CONSTITUENTSBy December 2019, humanity was challenged by a new infectious respiratory disease named coronavirus disease of 2019 or COVID-19. This... Repositório Covid-1914/11/2021 The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-reviewNowadays, one of the major global health concerns is coronavirus disease 2019 (COVID-19), which is caused by the severe acute... Repositório Covid-1912/11/2021 Com produção nacional, Blau Farmacêutica obtém registro do primeiro genérico da molécula Sugamadex no BrasilA Blau Farmacêutica (B3: BLAU3), uma das principais indústrias farmacêuticas da América Latina focada na produção de medicamentos de... Associado em foco12/11/2021 ABIFINA contribui para o Plano Estratégico da Farmacopeia BrasileiraABIFINA contribui para o Plano Estratégico da Farmacopeia Brasileira. Documento quinquenal é publicado no site da Anvisa contendo objetivos,... Acontece na ABIFINA11/11/2021 Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialWe report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like... Repositório Covid-1911/11/2021 Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trialConcomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of... Repositório Covid-1911/11/2021 Ourofino Saúde Animal é eleita a melhor empresa das Américas Latina e do Sul pela Animal HealthOurofino Saúde Animal foi eleita a melhor empresa das Américas Latina e do Sul no Animal Health Award. Inovação... Associado em foco
18/11/2021 SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic caused by it, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)... Repositório Covid-19
18/11/2021 Organ-specific genome diversity of replication-competent SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is not always confined to the respiratory system, as it impacts people... Repositório Covid-19
18/11/2021 Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2SARS-CoV-2 is the third coronavirus to have caused severe disease in humans in the last two decades, with approximately 5%... Repositório Covid-19
16/11/2021 Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2COVID-19, for which no confirmed therapeutic agents are available, has claimed over 48,14,000 lives globally. A feasible and quicker method... Repositório Covid-19
16/11/2021 Two years into COVID-19 – Lessons in SARS-CoV-2 and a perspective from papers in FEBS LettersThe 2019 outbreak of coronavirus disease (COVID-19) in Wuhan (Hubei province of China) has given rise to a pandemic spread... Repositório Covid-19
15/11/2021 COMPARISON OF REMDESIVIR AND FAVIPIRAVIR - THE ANTI-COVID-19 AGENTS MIMICKING PURINE RNA CONSTITUENTSBy December 2019, humanity was challenged by a new infectious respiratory disease named coronavirus disease of 2019 or COVID-19. This... Repositório Covid-19
14/11/2021 The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-reviewNowadays, one of the major global health concerns is coronavirus disease 2019 (COVID-19), which is caused by the severe acute... Repositório Covid-19
12/11/2021 Com produção nacional, Blau Farmacêutica obtém registro do primeiro genérico da molécula Sugamadex no BrasilA Blau Farmacêutica (B3: BLAU3), uma das principais indústrias farmacêuticas da América Latina focada na produção de medicamentos de... Associado em foco
12/11/2021 ABIFINA contribui para o Plano Estratégico da Farmacopeia BrasileiraABIFINA contribui para o Plano Estratégico da Farmacopeia Brasileira. Documento quinquenal é publicado no site da Anvisa contendo objetivos,... Acontece na ABIFINA
11/11/2021 Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialWe report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like... Repositório Covid-19
11/11/2021 Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trialConcomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of... Repositório Covid-19
11/11/2021 Ourofino Saúde Animal é eleita a melhor empresa das Américas Latina e do Sul pela Animal HealthOurofino Saúde Animal foi eleita a melhor empresa das Américas Latina e do Sul no Animal Health Award. Inovação... Associado em foco